Debiopharm to acquire products or companies to expand activities at Swiss manufacturing facility
Sangamo BioSciences surges as gene editing tech make cells repel HIV
Visit our sites for b2b sales and banking employees:
cafeb2bsales.com
cafebanking.com
Submit an article to cafepharma's CP Wire. Click here to find out more.
| Company | Average | Last 24h |
Increase |
|---|---|---|---|
| Wellpoint | 1 | 8 | 700 % |
| UV Flu Technologies | 1 | 7 | 600 % |
| Sangamo BioSciences | 5 | 34 | 580 % |
| Merck Serono | 1 | 6 | 500 % |
| Coastal Pharmaceuticals | 1 | 5 | 400 % |
| Tekmira Pharmaceuticals | 2 | 10 | 400 % |
| West-Ward Pharmaceuticals | 2 | 10 | 400 % |
| Allergan | 3 | 14 | 367 % |
| Endo Health Solutions | 5 | 21 | 320 % |
| cafepharma | 1 | 4 | 300 % |
| Company | Average | Last 24 hrs |
Increase |
|---|---|---|---|
| KV Pharmaceutical | 1 | 11 | 1000 % |
| Aastrom | 1 | 11 | 1000 % |
| AxoGen | 3 | 31 | 933 % |
| CAS Medical Systems | 1 | 10 | 900 % |
| Spectrum Pharmaceuticals | 5 | 47 | 840 % |
| Pluristem Therapeutics | 5 | 45 | 800 % |
| Durect Corporation | 1 | 8 | 700 % |
| Repligen | 6 | 47 | 683 % |
| Biostar Pharmaceuticals | 4 | 31 | 675 % |
| Second Genome | 1 | 7 | 600 % |